top of page
subopage-header-SK.png

News Archives

November 28, 2022

Epygenix Therapeutics to Present at the American Epilepsy Society 2022 Annual Meeting in Nashville

October 10, 2022

Epygenix Therapeutics to Host Investor Meetings at the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum

September 17, 2022

Epygenix Therapeutics to Present at UBS Biotechnology Virtual Private Company Symposium

July 21, 2022

Epygenix Therapeutics to Participate in RW Baird's Biotech Discovery Series

June 29, 2022

Epygenix Therapeutics Receives FDA Orphan Drug Designation for EPX-100 For Treatment of Ohtahara Syndrome

June 09, 2022

Epygenix Therapeutics to Provide Update at the Dravet Syndrome Foundation (DSF) 2022 Conference

June 01, 2022

First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome

May 23, 2022

Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer

May 20, 2022

Epygenix Therapeutics To Participate in UBS Healthcare Virtual 1x1 Day

March 23, 2022

Epygenix Therapeutics Announces Appointment of G. Michael Landis as Chief Financial Officer

March 15, 2022


Epygenix Therapeutics Announces Appointment of Darren Cline as CEO

February 16, 2022

Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome

August 30, 2021

Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome

August 02, 2021

Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome

August 02, 2021

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome

August 02, 2021

Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome

September 17, 2020

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

January 27, 2020

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

July 29, 2019

Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome

June 24, 2019

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

April 25, 2017

Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

bottom of page